nodes	percent_of_prediction	percent_of_DWPC	metapath
Escitalopram—CYP2C19—urine—urinary bladder cancer	0.00644	0.155	CbGeAlD
Escitalopram—CYP3A4—urine—urinary bladder cancer	0.00381	0.0919	CbGeAlD
Escitalopram—CYP2D6—urine—urinary bladder cancer	0.00375	0.0904	CbGeAlD
Escitalopram—CHRM1—prostate gland—urinary bladder cancer	0.00278	0.0671	CbGeAlD
Escitalopram—ADRA1A—prostate gland—urinary bladder cancer	0.00228	0.0551	CbGeAlD
Escitalopram—HRH1—prostate gland—urinary bladder cancer	0.00177	0.0426	CbGeAlD
Escitalopram—ADRA1A—epithelium—urinary bladder cancer	0.00168	0.0405	CbGeAlD
Escitalopram—HTR2C—female reproductive system—urinary bladder cancer	0.00161	0.0388	CbGeAlD
Escitalopram—ADRA1A—renal system—urinary bladder cancer	0.00156	0.0376	CbGeAlD
Escitalopram—SLC6A4—female reproductive system—urinary bladder cancer	0.00152	0.0367	CbGeAlD
Escitalopram—CHRM1—female reproductive system—urinary bladder cancer	0.00152	0.0366	CbGeAlD
Escitalopram—SLC6A2—female reproductive system—urinary bladder cancer	0.00134	0.0324	CbGeAlD
Escitalopram—HRH1—epithelium—urinary bladder cancer	0.0013	0.0313	CbGeAlD
Escitalopram—HRH1—smooth muscle tissue—urinary bladder cancer	0.00125	0.0302	CbGeAlD
Escitalopram—HRH1—urethra—urinary bladder cancer	0.00118	0.0286	CbGeAlD
Escitalopram—CYP2C19—vagina—urinary bladder cancer	0.00114	0.0275	CbGeAlD
Escitalopram—HRH1—female reproductive system—urinary bladder cancer	0.000965	0.0233	CbGeAlD
Escitalopram—CYP3A4—renal system—urinary bladder cancer	0.000931	0.0225	CbGeAlD
Escitalopram—CYP2D6—renal system—urinary bladder cancer	0.000916	0.0221	CbGeAlD
Escitalopram—HRH1—vagina—urinary bladder cancer	0.000872	0.0211	CbGeAlD
Escitalopram—SLC6A2—lymph node—urinary bladder cancer	0.000784	0.0189	CbGeAlD
Escitalopram—CYP3A4—female reproductive system—urinary bladder cancer	0.000746	0.018	CbGeAlD
Escitalopram—CYP2D6—female reproductive system—urinary bladder cancer	0.000734	0.0177	CbGeAlD
Escitalopram—HRH1—lymph node—urinary bladder cancer	0.000564	0.0136	CbGeAlD
Escitalopram—Visual impairment—Epirubicin—urinary bladder cancer	0.000246	0.000282	CcSEcCtD
Escitalopram—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000246	0.000282	CcSEcCtD
Escitalopram—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000245	0.000282	CcSEcCtD
Escitalopram—Chills—Methotrexate—urinary bladder cancer	0.000245	0.000281	CcSEcCtD
Escitalopram—Diarrhoea—Cisplatin—urinary bladder cancer	0.000241	0.000277	CcSEcCtD
Escitalopram—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000241	0.000277	CcSEcCtD
Escitalopram—Alopecia—Methotrexate—urinary bladder cancer	0.000241	0.000276	CcSEcCtD
Escitalopram—Vomiting—Gemcitabine—urinary bladder cancer	0.000241	0.000276	CcSEcCtD
Escitalopram—Bradycardia—Doxorubicin—urinary bladder cancer	0.00024	0.000276	CcSEcCtD
Escitalopram—Mental disorder—Methotrexate—urinary bladder cancer	0.000239	0.000274	CcSEcCtD
Escitalopram—Rash—Gemcitabine—urinary bladder cancer	0.000239	0.000274	CcSEcCtD
Escitalopram—Dermatitis—Gemcitabine—urinary bladder cancer	0.000239	0.000274	CcSEcCtD
Escitalopram—Eye disorder—Epirubicin—urinary bladder cancer	0.000238	0.000274	CcSEcCtD
Escitalopram—Hypersensitivity—Etoposide—urinary bladder cancer	0.000238	0.000273	CcSEcCtD
Escitalopram—Tinnitus—Epirubicin—urinary bladder cancer	0.000238	0.000273	CcSEcCtD
Escitalopram—Erythema—Methotrexate—urinary bladder cancer	0.000237	0.000272	CcSEcCtD
Escitalopram—Malnutrition—Methotrexate—urinary bladder cancer	0.000237	0.000272	CcSEcCtD
Escitalopram—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000237	0.000272	CcSEcCtD
Escitalopram—Headache—Gemcitabine—urinary bladder cancer	0.000237	0.000272	CcSEcCtD
Escitalopram—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000237	0.000272	CcSEcCtD
Escitalopram—Flushing—Epirubicin—urinary bladder cancer	0.000237	0.000272	CcSEcCtD
Escitalopram—Vomiting—Fluorouracil—urinary bladder cancer	0.000237	0.000272	CcSEcCtD
Escitalopram—Rhinitis—Doxorubicin—urinary bladder cancer	0.000237	0.000271	CcSEcCtD
Escitalopram—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000236	0.000271	CcSEcCtD
Escitalopram—Hepatitis—Doxorubicin—urinary bladder cancer	0.000236	0.000271	CcSEcCtD
Escitalopram—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000235	0.000269	CcSEcCtD
Escitalopram—Rash—Fluorouracil—urinary bladder cancer	0.000235	0.000269	CcSEcCtD
Escitalopram—Dermatitis—Fluorouracil—urinary bladder cancer	0.000235	0.000269	CcSEcCtD
Escitalopram—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000234	0.000269	CcSEcCtD
Escitalopram—Headache—Fluorouracil—urinary bladder cancer	0.000233	0.000268	CcSEcCtD
Escitalopram—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000233	0.000267	CcSEcCtD
Escitalopram—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000233	0.000267	CcSEcCtD
Escitalopram—Dysgeusia—Methotrexate—urinary bladder cancer	0.000232	0.000267	CcSEcCtD
Escitalopram—Asthenia—Etoposide—urinary bladder cancer	0.000232	0.000266	CcSEcCtD
Escitalopram—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000232	0.000266	CcSEcCtD
Escitalopram—Angiopathy—Epirubicin—urinary bladder cancer	0.000231	0.000266	CcSEcCtD
Escitalopram—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000231	0.000265	CcSEcCtD
Escitalopram—Immune system disorder—Epirubicin—urinary bladder cancer	0.00023	0.000264	CcSEcCtD
Escitalopram—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.00023	0.000264	CcSEcCtD
Escitalopram—Back pain—Methotrexate—urinary bladder cancer	0.00023	0.000263	CcSEcCtD
Escitalopram—Chills—Epirubicin—urinary bladder cancer	0.000229	0.000263	CcSEcCtD
Escitalopram—Pruritus—Etoposide—urinary bladder cancer	0.000229	0.000262	CcSEcCtD
Escitalopram—Arrhythmia—Epirubicin—urinary bladder cancer	0.000228	0.000261	CcSEcCtD
Escitalopram—Visual impairment—Doxorubicin—urinary bladder cancer	0.000227	0.000261	CcSEcCtD
Escitalopram—Alopecia—Epirubicin—urinary bladder cancer	0.000225	0.000259	CcSEcCtD
Escitalopram—Nausea—Gemcitabine—urinary bladder cancer	0.000225	0.000258	CcSEcCtD
Escitalopram—Vomiting—Cisplatin—urinary bladder cancer	0.000224	0.000257	CcSEcCtD
Escitalopram—Vision blurred—Methotrexate—urinary bladder cancer	0.000224	0.000257	CcSEcCtD
Escitalopram—Mental disorder—Epirubicin—urinary bladder cancer	0.000224	0.000256	CcSEcCtD
Escitalopram—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000223	0.000256	CcSEcCtD
Escitalopram—Rash—Cisplatin—urinary bladder cancer	0.000223	0.000255	CcSEcCtD
Escitalopram—Dermatitis—Cisplatin—urinary bladder cancer	0.000222	0.000255	CcSEcCtD
Escitalopram—Erythema—Epirubicin—urinary bladder cancer	0.000222	0.000255	CcSEcCtD
Escitalopram—Malnutrition—Epirubicin—urinary bladder cancer	0.000222	0.000255	CcSEcCtD
Escitalopram—Diarrhoea—Etoposide—urinary bladder cancer	0.000221	0.000254	CcSEcCtD
Escitalopram—Nausea—Fluorouracil—urinary bladder cancer	0.000221	0.000254	CcSEcCtD
Escitalopram—Eye disorder—Doxorubicin—urinary bladder cancer	0.000221	0.000253	CcSEcCtD
Escitalopram—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00022	0.000253	CcSEcCtD
Escitalopram—Tinnitus—Doxorubicin—urinary bladder cancer	0.00022	0.000252	CcSEcCtD
Escitalopram—Anaemia—Methotrexate—urinary bladder cancer	0.000219	0.000252	CcSEcCtD
Escitalopram—Flushing—Doxorubicin—urinary bladder cancer	0.000219	0.000251	CcSEcCtD
Escitalopram—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000219	0.000251	CcSEcCtD
Escitalopram—Flatulence—Epirubicin—urinary bladder cancer	0.000219	0.000251	CcSEcCtD
Escitalopram—Tension—Epirubicin—urinary bladder cancer	0.000218	0.00025	CcSEcCtD
Escitalopram—Dysgeusia—Epirubicin—urinary bladder cancer	0.000217	0.000249	CcSEcCtD
Escitalopram—Nervousness—Epirubicin—urinary bladder cancer	0.000216	0.000247	CcSEcCtD
Escitalopram—Back pain—Epirubicin—urinary bladder cancer	0.000215	0.000246	CcSEcCtD
Escitalopram—Angiopathy—Doxorubicin—urinary bladder cancer	0.000214	0.000246	CcSEcCtD
Escitalopram—Malaise—Methotrexate—urinary bladder cancer	0.000214	0.000246	CcSEcCtD
Escitalopram—Dizziness—Etoposide—urinary bladder cancer	0.000214	0.000245	CcSEcCtD
Escitalopram—Muscle spasms—Epirubicin—urinary bladder cancer	0.000214	0.000245	CcSEcCtD
Escitalopram—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000213	0.000245	CcSEcCtD
Escitalopram—Vertigo—Methotrexate—urinary bladder cancer	0.000213	0.000245	CcSEcCtD
Escitalopram—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000213	0.000244	CcSEcCtD
Escitalopram—Leukopenia—Methotrexate—urinary bladder cancer	0.000212	0.000244	CcSEcCtD
Escitalopram—Chills—Doxorubicin—urinary bladder cancer	0.000212	0.000243	CcSEcCtD
Escitalopram—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000211	0.000242	CcSEcCtD
Escitalopram—Nausea—Cisplatin—urinary bladder cancer	0.00021	0.000241	CcSEcCtD
Escitalopram—Vision blurred—Epirubicin—urinary bladder cancer	0.000209	0.00024	CcSEcCtD
Escitalopram—Alopecia—Doxorubicin—urinary bladder cancer	0.000209	0.000239	CcSEcCtD
Escitalopram—Cough—Methotrexate—urinary bladder cancer	0.000207	0.000238	CcSEcCtD
Escitalopram—Mental disorder—Doxorubicin—urinary bladder cancer	0.000207	0.000237	CcSEcCtD
Escitalopram—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000206	0.000236	CcSEcCtD
Escitalopram—Convulsion—Methotrexate—urinary bladder cancer	0.000206	0.000236	CcSEcCtD
Escitalopram—Vomiting—Etoposide—urinary bladder cancer	0.000206	0.000236	CcSEcCtD
Escitalopram—Erythema—Doxorubicin—urinary bladder cancer	0.000205	0.000236	CcSEcCtD
Escitalopram—Malnutrition—Doxorubicin—urinary bladder cancer	0.000205	0.000236	CcSEcCtD
Escitalopram—Anaemia—Epirubicin—urinary bladder cancer	0.000205	0.000235	CcSEcCtD
Escitalopram—Agitation—Epirubicin—urinary bladder cancer	0.000204	0.000234	CcSEcCtD
Escitalopram—Rash—Etoposide—urinary bladder cancer	0.000204	0.000234	CcSEcCtD
Escitalopram—Dermatitis—Etoposide—urinary bladder cancer	0.000204	0.000234	CcSEcCtD
Escitalopram—Headache—Etoposide—urinary bladder cancer	0.000203	0.000232	CcSEcCtD
Escitalopram—Flatulence—Doxorubicin—urinary bladder cancer	0.000202	0.000232	CcSEcCtD
Escitalopram—Arthralgia—Methotrexate—urinary bladder cancer	0.000202	0.000232	CcSEcCtD
Escitalopram—Chest pain—Methotrexate—urinary bladder cancer	0.000202	0.000232	CcSEcCtD
Escitalopram—Myalgia—Methotrexate—urinary bladder cancer	0.000202	0.000232	CcSEcCtD
Escitalopram—Tension—Doxorubicin—urinary bladder cancer	0.000202	0.000231	CcSEcCtD
Escitalopram—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000201	0.000231	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000201	0.00023	CcSEcCtD
Escitalopram—Malaise—Epirubicin—urinary bladder cancer	0.0002	0.00023	CcSEcCtD
Escitalopram—Discomfort—Methotrexate—urinary bladder cancer	0.0002	0.000229	CcSEcCtD
Escitalopram—Nervousness—Doxorubicin—urinary bladder cancer	0.0002	0.000229	CcSEcCtD
Escitalopram—Vertigo—Epirubicin—urinary bladder cancer	0.0002	0.000229	CcSEcCtD
Escitalopram—Syncope—Epirubicin—urinary bladder cancer	0.000199	0.000228	CcSEcCtD
Escitalopram—Leukopenia—Epirubicin—urinary bladder cancer	0.000199	0.000228	CcSEcCtD
Escitalopram—Back pain—Doxorubicin—urinary bladder cancer	0.000199	0.000228	CcSEcCtD
Escitalopram—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000198	0.000227	CcSEcCtD
Escitalopram—Palpitations—Epirubicin—urinary bladder cancer	0.000196	0.000225	CcSEcCtD
Escitalopram—Confusional state—Methotrexate—urinary bladder cancer	0.000195	0.000224	CcSEcCtD
Escitalopram—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000195	0.000224	CcSEcCtD
Escitalopram—Cough—Epirubicin—urinary bladder cancer	0.000194	0.000222	CcSEcCtD
Escitalopram—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000194	0.000222	CcSEcCtD
Escitalopram—Vision blurred—Doxorubicin—urinary bladder cancer	0.000194	0.000222	CcSEcCtD
Escitalopram—Convulsion—Epirubicin—urinary bladder cancer	0.000192	0.000221	CcSEcCtD
Escitalopram—Infection—Methotrexate—urinary bladder cancer	0.000192	0.000221	CcSEcCtD
Escitalopram—Nausea—Etoposide—urinary bladder cancer	0.000192	0.00022	CcSEcCtD
Escitalopram—Hypertension—Epirubicin—urinary bladder cancer	0.000192	0.00022	CcSEcCtD
Escitalopram—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000191	0.000219	CcSEcCtD
Escitalopram—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00019	0.000218	CcSEcCtD
Escitalopram—Anaemia—Doxorubicin—urinary bladder cancer	0.00019	0.000218	CcSEcCtD
Escitalopram—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.00019	0.000218	CcSEcCtD
Escitalopram—Chest pain—Epirubicin—urinary bladder cancer	0.000189	0.000217	CcSEcCtD
Escitalopram—Myalgia—Epirubicin—urinary bladder cancer	0.000189	0.000217	CcSEcCtD
Escitalopram—Arthralgia—Epirubicin—urinary bladder cancer	0.000189	0.000217	CcSEcCtD
Escitalopram—Agitation—Doxorubicin—urinary bladder cancer	0.000189	0.000217	CcSEcCtD
Escitalopram—Anxiety—Epirubicin—urinary bladder cancer	0.000188	0.000216	CcSEcCtD
Escitalopram—Skin disorder—Methotrexate—urinary bladder cancer	0.000188	0.000216	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000188	0.000215	CcSEcCtD
Escitalopram—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000187	0.000215	CcSEcCtD
Escitalopram—Discomfort—Epirubicin—urinary bladder cancer	0.000187	0.000214	CcSEcCtD
Escitalopram—Malaise—Doxorubicin—urinary bladder cancer	0.000185	0.000213	CcSEcCtD
Escitalopram—Dry mouth—Epirubicin—urinary bladder cancer	0.000185	0.000212	CcSEcCtD
Escitalopram—Vertigo—Doxorubicin—urinary bladder cancer	0.000185	0.000212	CcSEcCtD
Escitalopram—Anorexia—Methotrexate—urinary bladder cancer	0.000185	0.000212	CcSEcCtD
Escitalopram—Syncope—Doxorubicin—urinary bladder cancer	0.000184	0.000211	CcSEcCtD
Escitalopram—Leukopenia—Doxorubicin—urinary bladder cancer	0.000184	0.000211	CcSEcCtD
Escitalopram—Confusional state—Epirubicin—urinary bladder cancer	0.000183	0.00021	CcSEcCtD
Escitalopram—Palpitations—Doxorubicin—urinary bladder cancer	0.000182	0.000208	CcSEcCtD
Escitalopram—Oedema—Epirubicin—urinary bladder cancer	0.000181	0.000208	CcSEcCtD
Escitalopram—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000181	0.000208	CcSEcCtD
Escitalopram—Hypotension—Methotrexate—urinary bladder cancer	0.000181	0.000208	CcSEcCtD
Escitalopram—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000181	0.000207	CcSEcCtD
Escitalopram—Infection—Epirubicin—urinary bladder cancer	0.00018	0.000207	CcSEcCtD
Escitalopram—Cough—Doxorubicin—urinary bladder cancer	0.000179	0.000206	CcSEcCtD
Escitalopram—Shock—Epirubicin—urinary bladder cancer	0.000178	0.000205	CcSEcCtD
Escitalopram—Convulsion—Doxorubicin—urinary bladder cancer	0.000178	0.000204	CcSEcCtD
Escitalopram—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000178	0.000204	CcSEcCtD
Escitalopram—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000177	0.000204	CcSEcCtD
Escitalopram—Hypertension—Doxorubicin—urinary bladder cancer	0.000177	0.000204	CcSEcCtD
Escitalopram—Tachycardia—Epirubicin—urinary bladder cancer	0.000177	0.000203	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000176	0.000202	CcSEcCtD
Escitalopram—Skin disorder—Epirubicin—urinary bladder cancer	0.000176	0.000202	CcSEcCtD
Escitalopram—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000175	0.000201	CcSEcCtD
Escitalopram—Insomnia—Methotrexate—urinary bladder cancer	0.000175	0.000201	CcSEcCtD
Escitalopram—Myalgia—Doxorubicin—urinary bladder cancer	0.000175	0.000201	CcSEcCtD
Escitalopram—Arthralgia—Doxorubicin—urinary bladder cancer	0.000175	0.000201	CcSEcCtD
Escitalopram—Chest pain—Doxorubicin—urinary bladder cancer	0.000175	0.000201	CcSEcCtD
Escitalopram—Anxiety—Doxorubicin—urinary bladder cancer	0.000174	0.0002	CcSEcCtD
Escitalopram—Paraesthesia—Methotrexate—urinary bladder cancer	0.000174	0.0002	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000174	0.000199	CcSEcCtD
Escitalopram—Discomfort—Doxorubicin—urinary bladder cancer	0.000173	0.000198	CcSEcCtD
Escitalopram—Anorexia—Epirubicin—urinary bladder cancer	0.000173	0.000198	CcSEcCtD
Escitalopram—Dyspnoea—Methotrexate—urinary bladder cancer	0.000173	0.000198	CcSEcCtD
Escitalopram—Somnolence—Methotrexate—urinary bladder cancer	0.000172	0.000198	CcSEcCtD
Escitalopram—Dry mouth—Doxorubicin—urinary bladder cancer	0.000171	0.000196	CcSEcCtD
Escitalopram—Dyspepsia—Methotrexate—urinary bladder cancer	0.00017	0.000196	CcSEcCtD
Escitalopram—Hypotension—Epirubicin—urinary bladder cancer	0.000169	0.000194	CcSEcCtD
Escitalopram—Confusional state—Doxorubicin—urinary bladder cancer	0.000169	0.000194	CcSEcCtD
Escitalopram—Decreased appetite—Methotrexate—urinary bladder cancer	0.000168	0.000193	CcSEcCtD
Escitalopram—Oedema—Doxorubicin—urinary bladder cancer	0.000168	0.000192	CcSEcCtD
Escitalopram—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000168	0.000192	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000167	0.000192	CcSEcCtD
Escitalopram—Fatigue—Methotrexate—urinary bladder cancer	0.000167	0.000192	CcSEcCtD
Escitalopram—Infection—Doxorubicin—urinary bladder cancer	0.000167	0.000191	CcSEcCtD
Escitalopram—Pain—Methotrexate—urinary bladder cancer	0.000166	0.00019	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000165	0.000189	CcSEcCtD
Escitalopram—Shock—Doxorubicin—urinary bladder cancer	0.000165	0.000189	CcSEcCtD
Escitalopram—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000164	0.000189	CcSEcCtD
Escitalopram—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000164	0.000188	CcSEcCtD
Escitalopram—Insomnia—Epirubicin—urinary bladder cancer	0.000164	0.000188	CcSEcCtD
Escitalopram—Tachycardia—Doxorubicin—urinary bladder cancer	0.000164	0.000188	CcSEcCtD
Escitalopram—Skin disorder—Doxorubicin—urinary bladder cancer	0.000163	0.000187	CcSEcCtD
Escitalopram—Paraesthesia—Epirubicin—urinary bladder cancer	0.000163	0.000187	CcSEcCtD
Escitalopram—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000162	0.000186	CcSEcCtD
Escitalopram—Dyspnoea—Epirubicin—urinary bladder cancer	0.000162	0.000185	CcSEcCtD
Escitalopram—Somnolence—Epirubicin—urinary bladder cancer	0.000161	0.000185	CcSEcCtD
Escitalopram—Anorexia—Doxorubicin—urinary bladder cancer	0.00016	0.000183	CcSEcCtD
Escitalopram—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00016	0.000183	CcSEcCtD
Escitalopram—Dyspepsia—Epirubicin—urinary bladder cancer	0.00016	0.000183	CcSEcCtD
Escitalopram—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000158	0.000182	CcSEcCtD
Escitalopram—Decreased appetite—Epirubicin—urinary bladder cancer	0.000158	0.000181	CcSEcCtD
Escitalopram—Hypotension—Doxorubicin—urinary bladder cancer	0.000157	0.00018	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000156	0.00018	CcSEcCtD
Escitalopram—Fatigue—Epirubicin—urinary bladder cancer	0.000156	0.000179	CcSEcCtD
Escitalopram—Pain—Epirubicin—urinary bladder cancer	0.000155	0.000178	CcSEcCtD
Escitalopram—Constipation—Epirubicin—urinary bladder cancer	0.000155	0.000178	CcSEcCtD
Escitalopram—Urticaria—Methotrexate—urinary bladder cancer	0.000154	0.000177	CcSEcCtD
Escitalopram—Abdominal pain—Methotrexate—urinary bladder cancer	0.000153	0.000176	CcSEcCtD
Escitalopram—Body temperature increased—Methotrexate—urinary bladder cancer	0.000153	0.000176	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000153	0.000175	CcSEcCtD
Escitalopram—Insomnia—Doxorubicin—urinary bladder cancer	0.000152	0.000174	CcSEcCtD
Escitalopram—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000151	0.000173	CcSEcCtD
Escitalopram—Dyspnoea—Doxorubicin—urinary bladder cancer	0.00015	0.000172	CcSEcCtD
Escitalopram—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000149	0.000171	CcSEcCtD
Escitalopram—Somnolence—Doxorubicin—urinary bladder cancer	0.000149	0.000171	CcSEcCtD
Escitalopram—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000148	0.00017	CcSEcCtD
Escitalopram—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000148	0.000169	CcSEcCtD
Escitalopram—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000146	0.000167	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000145	0.000166	CcSEcCtD
Escitalopram—Fatigue—Doxorubicin—urinary bladder cancer	0.000145	0.000166	CcSEcCtD
Escitalopram—Urticaria—Epirubicin—urinary bladder cancer	0.000144	0.000165	CcSEcCtD
Escitalopram—Constipation—Doxorubicin—urinary bladder cancer	0.000143	0.000165	CcSEcCtD
Escitalopram—Pain—Doxorubicin—urinary bladder cancer	0.000143	0.000165	CcSEcCtD
Escitalopram—Abdominal pain—Epirubicin—urinary bladder cancer	0.000143	0.000164	CcSEcCtD
Escitalopram—Body temperature increased—Epirubicin—urinary bladder cancer	0.000143	0.000164	CcSEcCtD
Escitalopram—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000143	0.000164	CcSEcCtD
Escitalopram—Asthenia—Methotrexate—urinary bladder cancer	0.000139	0.000159	CcSEcCtD
Escitalopram—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000138	0.000159	CcSEcCtD
Escitalopram—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000137	0.000157	CcSEcCtD
Escitalopram—Pruritus—Methotrexate—urinary bladder cancer	0.000137	0.000157	CcSEcCtD
Escitalopram—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000134	0.000153	CcSEcCtD
Escitalopram—Urticaria—Doxorubicin—urinary bladder cancer	0.000133	0.000153	CcSEcCtD
Escitalopram—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000133	0.000152	CcSEcCtD
Escitalopram—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000133	0.000152	CcSEcCtD
Escitalopram—Diarrhoea—Methotrexate—urinary bladder cancer	0.000133	0.000152	CcSEcCtD
Escitalopram—Asthenia—Epirubicin—urinary bladder cancer	0.00013	0.000149	CcSEcCtD
Escitalopram—Pruritus—Epirubicin—urinary bladder cancer	0.000128	0.000147	CcSEcCtD
Escitalopram—Dizziness—Methotrexate—urinary bladder cancer	0.000128	0.000147	CcSEcCtD
Escitalopram—Diarrhoea—Epirubicin—urinary bladder cancer	0.000124	0.000142	CcSEcCtD
Escitalopram—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000124	0.000142	CcSEcCtD
Escitalopram—Vomiting—Methotrexate—urinary bladder cancer	0.000123	0.000141	CcSEcCtD
Escitalopram—Rash—Methotrexate—urinary bladder cancer	0.000122	0.00014	CcSEcCtD
Escitalopram—Dermatitis—Methotrexate—urinary bladder cancer	0.000122	0.00014	CcSEcCtD
Escitalopram—Headache—Methotrexate—urinary bladder cancer	0.000121	0.000139	CcSEcCtD
Escitalopram—Asthenia—Doxorubicin—urinary bladder cancer	0.00012	0.000138	CcSEcCtD
Escitalopram—Dizziness—Epirubicin—urinary bladder cancer	0.00012	0.000137	CcSEcCtD
Escitalopram—Pruritus—Doxorubicin—urinary bladder cancer	0.000119	0.000136	CcSEcCtD
Escitalopram—Vomiting—Epirubicin—urinary bladder cancer	0.000115	0.000132	CcSEcCtD
Escitalopram—Nausea—Methotrexate—urinary bladder cancer	0.000115	0.000132	CcSEcCtD
Escitalopram—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000115	0.000132	CcSEcCtD
Escitalopram—Rash—Epirubicin—urinary bladder cancer	0.000114	0.000131	CcSEcCtD
Escitalopram—Dermatitis—Epirubicin—urinary bladder cancer	0.000114	0.000131	CcSEcCtD
Escitalopram—Headache—Epirubicin—urinary bladder cancer	0.000114	0.00013	CcSEcCtD
Escitalopram—Dizziness—Doxorubicin—urinary bladder cancer	0.000111	0.000127	CcSEcCtD
Escitalopram—Nausea—Epirubicin—urinary bladder cancer	0.000108	0.000124	CcSEcCtD
Escitalopram—Vomiting—Doxorubicin—urinary bladder cancer	0.000107	0.000122	CcSEcCtD
Escitalopram—Rash—Doxorubicin—urinary bladder cancer	0.000106	0.000121	CcSEcCtD
Escitalopram—Dermatitis—Doxorubicin—urinary bladder cancer	0.000106	0.000121	CcSEcCtD
Escitalopram—Headache—Doxorubicin—urinary bladder cancer	0.000105	0.000121	CcSEcCtD
Escitalopram—Nausea—Doxorubicin—urinary bladder cancer	9.96e-05	0.000114	CcSEcCtD
Escitalopram—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	7.1e-05	0.000817	CbGpPWpGaD
Escitalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	7.05e-05	0.000812	CbGpPWpGaD
Escitalopram—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	7e-05	0.000806	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HDAC4—urinary bladder cancer	6.98e-05	0.000804	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HDAC4—urinary bladder cancer	6.96e-05	0.000801	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	6.86e-05	0.00079	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—NAT1—urinary bladder cancer	6.86e-05	0.00079	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HDAC4—urinary bladder cancer	6.85e-05	0.000789	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	6.82e-05	0.000786	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—GLI1—urinary bladder cancer	6.75e-05	0.000777	CbGpPWpGaD
Escitalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	6.66e-05	0.000767	CbGpPWpGaD
Escitalopram—SLC6A3—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	6.59e-05	0.000759	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.58e-05	0.000757	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	6.27e-05	0.000723	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	6.19e-05	0.000713	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	6.17e-05	0.00071	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	6.14e-05	0.000707	CbGpPWpGaD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	6.11e-05	0.000703	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	6.09e-05	0.000701	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	6.07e-05	0.000699	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	5.99e-05	0.00069	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—GLI1—urinary bladder cancer	5.85e-05	0.000674	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—GLI1—urinary bladder cancer	5.83e-05	0.000671	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.83e-05	0.000671	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	5.8e-05	0.000668	CbGpPWpGaD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	5.77e-05	0.000664	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	5.75e-05	0.000662	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—GLI1—urinary bladder cancer	5.74e-05	0.000661	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	5.66e-05	0.000652	CbGpPWpGaD
Escitalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	5.66e-05	0.000652	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	5.65e-05	0.000651	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	5.65e-05	0.000651	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—CXCL8—urinary bladder cancer	5.44e-05	0.000626	CbGpPWpGaD
Escitalopram—CHRM1—Circadian rythm related genes—TP53—urinary bladder cancer	5.39e-05	0.000621	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	5.33e-05	0.000614	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	5.2e-05	0.000599	CbGpPWpGaD
Escitalopram—SLC6A3—Neuronal System—HRAS—urinary bladder cancer	5.05e-05	0.000582	CbGpPWpGaD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	4.9e-05	0.000565	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	4.89e-05	0.000563	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	4.81e-05	0.000554	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	4.73e-05	0.000545	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—CXCL8—urinary bladder cancer	4.71e-05	0.000543	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—CXCL8—urinary bladder cancer	4.7e-05	0.000541	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—RBX1—urinary bladder cancer	4.63e-05	0.000533	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—CXCL8—urinary bladder cancer	4.62e-05	0.000532	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.53e-05	0.000522	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—TYMP—urinary bladder cancer	4.52e-05	0.00052	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	4.49e-05	0.000516	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NAT1—urinary bladder cancer	4.49e-05	0.000516	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TSC1—urinary bladder cancer	4.35e-05	0.000501	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.34e-05	0.0005	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—TYMP—urinary bladder cancer	4.16e-05	0.000479	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—JAG1—urinary bladder cancer	4.14e-05	0.000477	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.1e-05	0.000472	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—NAT2—urinary bladder cancer	4.09e-05	0.000471	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—RBX1—urinary bladder cancer	4.01e-05	0.000462	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—RBX1—urinary bladder cancer	4e-05	0.00046	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—RBX1—urinary bladder cancer	3.93e-05	0.000453	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TSC1—urinary bladder cancer	3.77e-05	0.000434	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—NAT2—urinary bladder cancer	3.76e-05	0.000433	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TSC1—urinary bladder cancer	3.76e-05	0.000433	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TSC1—urinary bladder cancer	3.7e-05	0.000426	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.69e-05	0.000425	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—JAG1—urinary bladder cancer	3.59e-05	0.000413	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—JAG1—urinary bladder cancer	3.58e-05	0.000412	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—RRM2—urinary bladder cancer	3.53e-05	0.000406	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—JAG1—urinary bladder cancer	3.52e-05	0.000405	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—RHOA—urinary bladder cancer	3.5e-05	0.000403	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.49e-05	0.000402	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.4e-05	0.000391	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—S100B—urinary bladder cancer	3.35e-05	0.000386	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ENO2—urinary bladder cancer	3.27e-05	0.000376	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	3.27e-05	0.000376	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.25e-05	0.000374	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—RRM2—urinary bladder cancer	3.24e-05	0.000374	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—RHOA—urinary bladder cancer	3.18e-05	0.000366	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	3.17e-05	0.000365	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.12e-05	0.000359	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.07e-05	0.000354	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—RHOA—urinary bladder cancer	3.03e-05	0.000349	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—RHOA—urinary bladder cancer	3.02e-05	0.000348	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NCOR1—urinary bladder cancer	3.02e-05	0.000347	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	3e-05	0.000346	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ENO2—urinary bladder cancer	3e-05	0.000346	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—RHOA—urinary bladder cancer	2.98e-05	0.000343	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—IL2—urinary bladder cancer	2.94e-05	0.000338	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	2.91e-05	0.000336	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—S100B—urinary bladder cancer	2.91e-05	0.000335	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—S100B—urinary bladder cancer	2.9e-05	0.000334	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—S100B—urinary bladder cancer	2.85e-05	0.000328	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—CXCL8—urinary bladder cancer	2.79e-05	0.000321	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—RHOA—urinary bladder cancer	2.75e-05	0.000317	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—RHOA—urinary bladder cancer	2.75e-05	0.000316	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.72e-05	0.000313	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—RHOA—urinary bladder cancer	2.7e-05	0.000311	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—IL2—urinary bladder cancer	2.67e-05	0.000307	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—CXCL8—urinary bladder cancer	2.66e-05	0.000307	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TERT—urinary bladder cancer	2.66e-05	0.000306	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—CXCL8—urinary bladder cancer	2.65e-05	0.000306	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—NQO1—urinary bladder cancer	2.63e-05	0.000303	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—CXCL8—urinary bladder cancer	2.61e-05	0.000301	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NCOR1—urinary bladder cancer	2.61e-05	0.000301	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NCOR1—urinary bladder cancer	2.6e-05	0.0003	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NCOR1—urinary bladder cancer	2.56e-05	0.000295	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.56e-05	0.000294	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—IL2—urinary bladder cancer	2.54e-05	0.000293	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—IL2—urinary bladder cancer	2.54e-05	0.000292	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—IL2—urinary bladder cancer	2.5e-05	0.000288	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.46e-05	0.000283	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—FGFR3—urinary bladder cancer	2.44e-05	0.000281	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2.42e-05	0.000279	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—CXCL8—urinary bladder cancer	2.42e-05	0.000278	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—CXCL8—urinary bladder cancer	2.41e-05	0.000278	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—CXCL8—urinary bladder cancer	2.37e-05	0.000273	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ESR1—urinary bladder cancer	2.37e-05	0.000273	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—IL2—urinary bladder cancer	2.31e-05	0.000266	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—IL2—urinary bladder cancer	2.3e-05	0.000265	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TERT—urinary bladder cancer	2.3e-05	0.000265	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TERT—urinary bladder cancer	2.3e-05	0.000264	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—IL2—urinary bladder cancer	2.27e-05	0.000261	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TERT—urinary bladder cancer	2.26e-05	0.00026	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.23e-05	0.000257	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	2.2e-05	0.000253	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.12e-05	0.000245	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.12e-05	0.000244	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—FGFR3—urinary bladder cancer	2.11e-05	0.000243	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—FGFR3—urinary bladder cancer	2.11e-05	0.000243	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CREBBP—urinary bladder cancer	2.08e-05	0.000239	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—FGFR3—urinary bladder cancer	2.07e-05	0.000239	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ESR1—urinary bladder cancer	2.05e-05	0.000236	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IGF1—urinary bladder cancer	2.05e-05	0.000236	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ESR1—urinary bladder cancer	2.05e-05	0.000236	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—TYMS—urinary bladder cancer	2.04e-05	0.000235	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—EGFR—urinary bladder cancer	2.04e-05	0.000235	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.02e-05	0.000233	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	2.02e-05	0.000232	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	2.02e-05	0.000232	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ESR1—urinary bladder cancer	2.01e-05	0.000232	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.96e-05	0.000226	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.96e-05	0.000226	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.93e-05	0.000223	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—KRAS—urinary bladder cancer	1.93e-05	0.000222	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.91e-05	0.000219	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.9e-05	0.000219	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.88e-05	0.000216	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—RHOA—urinary bladder cancer	1.88e-05	0.000216	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.86e-05	0.000214	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.86e-05	0.000214	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CREBBP—urinary bladder cancer	1.8e-05	0.000207	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CREBBP—urinary bladder cancer	1.79e-05	0.000206	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.78e-05	0.000205	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.78e-05	0.000205	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IGF1—urinary bladder cancer	1.78e-05	0.000205	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IGF1—urinary bladder cancer	1.77e-05	0.000204	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	1.77e-05	0.000204	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CREBBP—urinary bladder cancer	1.77e-05	0.000203	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—EGFR—urinary bladder cancer	1.76e-05	0.000203	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.75e-05	0.000201	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IGF1—urinary bladder cancer	1.74e-05	0.000201	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	1.74e-05	0.0002	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—EGFR—urinary bladder cancer	1.73e-05	0.0002	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	1.67e-05	0.000192	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—KRAS—urinary bladder cancer	1.66e-05	0.000192	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	1.65e-05	0.00019	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.64e-05	0.000189	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	1.64e-05	0.000189	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	1.64e-05	0.000189	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	1.63e-05	0.000187	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—RHOA—urinary bladder cancer	1.62e-05	0.000187	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	1.6e-05	0.000184	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.58e-05	0.000182	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	1.58e-05	0.000181	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	1.54e-05	0.000177	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	1.51e-05	0.000173	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ERBB2—urinary bladder cancer	1.5e-05	0.000173	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	1.49e-05	0.000172	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	1.49e-05	0.000171	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	1.48e-05	0.000171	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.48e-05	0.00017	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.45e-05	0.000167	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	1.43e-05	0.000165	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CXCL8—urinary bladder cancer	1.42e-05	0.000164	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	1.42e-05	0.000163	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—HRAS—urinary bladder cancer	1.41e-05	0.000163	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	1.41e-05	0.000163	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	1.4e-05	0.000161	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	1.39e-05	0.00016	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.39e-05	0.00016	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	1.37e-05	0.000158	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IL2—urinary bladder cancer	1.37e-05	0.000157	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IL2—urinary bladder cancer	1.36e-05	0.000157	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	1.34e-05	0.000154	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	1.33e-05	0.000153	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.33e-05	0.000153	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CCND1—urinary bladder cancer	1.33e-05	0.000153	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.32e-05	0.000152	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	1.31e-05	0.00015	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	1.29e-05	0.000149	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MMP9—urinary bladder cancer	1.29e-05	0.000148	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.29e-05	0.000148	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	1.28e-05	0.000148	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.28e-05	0.000148	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PTEN—urinary bladder cancer	1.28e-05	0.000147	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.28e-05	0.000147	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	1.27e-05	0.000146	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.26e-05	0.000145	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	1.26e-05	0.000145	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	1.23e-05	0.000142	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.23e-05	0.000141	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—EP300—urinary bladder cancer	1.23e-05	0.000141	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EP300—urinary bladder cancer	1.22e-05	0.000141	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.21e-05	0.00014	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.21e-05	0.00014	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	1.21e-05	0.000139	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	1.2e-05	0.000138	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—SRC—urinary bladder cancer	1.19e-05	0.000137	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—SRC—urinary bladder cancer	1.19e-05	0.000137	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	1.17e-05	0.000135	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.16e-05	0.000134	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.14e-05	0.000131	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	1.14e-05	0.000131	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.14e-05	0.000131	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.07e-05	0.000124	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MYC—urinary bladder cancer	1.07e-05	0.000123	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MYC—urinary bladder cancer	1.06e-05	0.000123	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	1.05e-05	0.000121	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.05e-05	0.000121	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	1.04e-05	0.00012	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EGFR—urinary bladder cancer	1.04e-05	0.00012	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	1.02e-05	0.000118	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	1.01e-05	0.000117	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTEN—urinary bladder cancer	9.92e-06	0.000114	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	9.86e-06	0.000114	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—KRAS—urinary bladder cancer	9.83e-06	0.000113	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	9.68e-06	0.000111	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	9.68e-06	0.000111	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—EP300—urinary bladder cancer	9.46e-06	0.000109	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTEN—urinary bladder cancer	9.13e-06	0.000105	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TP53—urinary bladder cancer	8.77e-06	0.000101	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TP53—urinary bladder cancer	8.74e-06	0.000101	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—EP300—urinary bladder cancer	8.7e-06	0.0001	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PPARG—urinary bladder cancer	8.7e-06	0.0001	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	8.6e-06	9.91e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	8.38e-06	9.66e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HRAS—urinary bladder cancer	8.36e-06	9.62e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	8.36e-06	9.62e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	8.23e-06	9.47e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	6.84e-06	7.88e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTEN—urinary bladder cancer	5.97e-06	6.87e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—EP300—urinary bladder cancer	5.69e-06	6.55e-05	CbGpPWpGaD
